Clinical Trial Update: Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 [Phase 3]

View source ↗

Summary

Long-term extension study in multiple sclerosis participants completed following a prior trial; terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BIIB019

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2019-12-04